RegenXBio has filed an amended S-1 form with the Securities and Exchange Commission (SEC) regarding the anticipated pricing of its initial public offering (IPO). Previously, terms for this offering were set as approximately 5.556 million shares priced in the range of $17 to $19 apiece. However, this most recent filing indicates that the anticipated price will be $22, well above the expected range.

The company intends to file on the Nasdaq Global Market under the symbol RGNX, and the offering is expected to take place either Thursday or Friday. The underwriters for the offering are Morgan Stanley, Merrill Lynch, Piper Jaffray and Chardan Capital Markets.

This is a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy. The proprietary AAV gene delivery platform consists of exclusive rights to over 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10 (NAV Vectors).

The company’s mission is to transform the lives of patients suffering from severe diseases with significant unmet medical needs by developing and commercializing gene therapy products administered directly into the body, based on its NAV Technology Platform. It seeks to accomplish its mission through a combination of internal development efforts and the efforts of third-party licensees.

The NAV Technology Platform currently is being applied in the development of 23 product candidates for a variety of diseases, including five internally developed product candidates and 18 partnered product candidates developed by the company’s NAV technology licensees.

ALSO READ: How GW Pharma’s Newest Cannabinoid Trial Is a Game Changer

The most advanced internally developed candidates include programs for the treatment of two severe, rare genetic diseases: homozygous familial hypercholesterolemia and mucopolysaccharidosis type I. The company expects these programs to enter Phase 1/2 clinical trials in the first half of 2016. It also has a program for wet age-related macular degeneration that is in the preclinical stage, which is expected to file an Investigational New Drug Application in the second half of 2016. RegenXBio plans to build internal gene therapy franchises in the metabolic, neurodegenerative and retinal therapeutic areas, as well as develop multiple product candidates in these and other areas.

The company intends to use the proceeds from the offering to fund the research and development of its product candidates. The remainder of the proceeds will go toward working capital and general corporate purposes.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.